272 related articles for article (PubMed ID: 18288213)
1. Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer.
Jacobs F; Snoeys J; Feng Y; Van Craeyveld E; Lievens J; Armentano D; Cheng SH; De Geest B
Gene Ther; 2008 Apr; 15(8):594-603. PubMed ID: 18288213
[TBL] [Abstract][Full Text] [Related]
2. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
3. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
4. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer.
Lievens J; Snoeys J; Vekemans K; Van Linthout S; de Zanger R; Collen D; Wisse E; De Geest B
Gene Ther; 2004 Oct; 11(20):1523-31. PubMed ID: 15269718
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
6. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I.
Van Linthout S; Collen D; De Geest B
Hum Gene Ther; 2002 May; 13(7):829-40. PubMed ID: 11975849
[TBL] [Abstract][Full Text] [Related]
7. Sustained expression of human apo A-I following adenoviral gene transfer in mice.
De Geest B; Van Linthout S; Collen D
Gene Ther; 2001 Jan; 8(2):121-7. PubMed ID: 11313781
[TBL] [Abstract][Full Text] [Related]
8. Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer.
Snoeys J; Mertens G; Lievens J; van Berkel T; Collen D; Biessen EA; De Geest B
Mol Ther; 2006 Jan; 13(1):98-107. PubMed ID: 16112619
[TBL] [Abstract][Full Text] [Related]
9. Sustained liver-specific transgene expression from the albumin promoter in mice following hydrodynamic plasmid DNA delivery.
Wooddell CI; Reppen T; Wolff JA; Herweijer H
J Gene Med; 2008 May; 10(5):551-63. PubMed ID: 18330848
[TBL] [Abstract][Full Text] [Related]
10. The impact of antigen expression in antigen-presenting cells on humoral immune responses against the transgene product.
Feng Y; Jacobs F; Van Craeyveld E; Lievens J; Snoeys J; Van Linthout S; De Geest B
Gene Ther; 2010 Feb; 17(2):288-93. PubMed ID: 19759564
[TBL] [Abstract][Full Text] [Related]
11. Transgene loss and changes in the promoter methylation status as determinants for expression duration in nonviral gene transfer for factor IX.
Schüttrumpf J; Milanov P; Abriss D; Roth S; Tonn T; Seifried E
Hum Gene Ther; 2011 Jan; 22(1):101-6. PubMed ID: 20677911
[TBL] [Abstract][Full Text] [Related]
12. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte-specific gene expression from integrated lentiviral vectors.
Nash KL; Jamil B; Maguire AJ; Alexander GJ; Lever AM
J Gene Med; 2004 Sep; 6(9):974-83. PubMed ID: 15352070
[TBL] [Abstract][Full Text] [Related]
14. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector.
Wang Q; Greenburg G; Bunch D; Farson D; Finer MH
Gene Ther; 1997 May; 4(5):393-400. PubMed ID: 9274715
[TBL] [Abstract][Full Text] [Related]
15. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.
Fang B; Wang H; Gordon G; Bellinger DA; Read MS; Brinkhous KM; Woo SL; Eisensmith RC
Gene Ther; 1996 Mar; 3(3):217-22. PubMed ID: 8646552
[TBL] [Abstract][Full Text] [Related]
16. New tools for the generation of E1- and/or E3-substituted adenoviral vectors.
Danthinne X; Werth E
Gene Ther; 2000 Jan; 7(1):80-7. PubMed ID: 10680020
[TBL] [Abstract][Full Text] [Related]
17. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
18. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer.
De Geest B; Van Linthout S; Lox M; Collen D; Holvoet P
Hum Gene Ther; 2000 Jan; 11(1):101-12. PubMed ID: 10646643
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer.
Guo ZS; Wang LH; Eisensmith RC; Woo SL
Gene Ther; 1996 Sep; 3(9):802-10. PubMed ID: 8875229
[TBL] [Abstract][Full Text] [Related]
20. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy.
Cao B; Bruder J; Kovesdi I; Huard J
Gene Ther; 2004 Sep; 11(17):1321-30. PubMed ID: 15175641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
